Plasma biomarkers pertaining to the underlying pathophysiology of Alzheimer’s disease have recently become available (for example, amyloid beta and phosphorylated tau). The utility of these markers poses a question for clinicians (now and in the future): are plasma biomarkers for Alzheimer’s disease are ready for clinical use at this time?
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jack, C. R. Jr. et al. Alzheimers Dement. 14, 535–562 (2018).
Dubois, B. et al. Lancet Neurol. 20, 484–496 (2021).
West, T. et al. Mol. Neurodegener. 16, 30 (2021).
Karikari, T. K. et al. Lancet Neurol. 19, 422–433 (2020).
Janelidze, S. et al. Nat. Med. 26, 379–386 (2020).
Barthélemy, N. R. et al. Nat. Med. 26, 398–407 (2020).
Palmqvist, S. et al. J. Am. Med. Assoc. 324, 772–781 (2020).
Cullen, N. C. et al. Nat. Aging 1, 114–123 (2021).
Palmqvist, S. et al. Nat. Med. 27, 1034–1042 (2021).
Ossenkoppele, R. et al. EMBO Mol. Med. 13, e14398 (2021).
Cummings, J. et al. J. Prev. Alzheimers Dis. 8, 398–410 (2021).
Mintun, M. A. et al. N. Engl. J. Med. 384, 1691–1704 (2021).
Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H. & Blennow, K. JAMA Neurol. 76, 791–799 (2019).
Morris, J. C. et al. JAMA Neurol. 76, 264–273 (2019).
Gauthier, S., Therriault, J., Pascoal, T. & Rosa-Neto, P. Expert Rev. Neurother. 20, 1211–1213 (2020).
Petersen, R. C. Neurology 91, 395–402 (2018).
Acknowledgements
Funding was provided by NIH National Institute on Aging P30 AG062677 and U01 AG006786.
Author information
Authors and Affiliations
Contributions
R.C.P. is the sole author of this Comment.
Corresponding author
Ethics declarations
Competing interests
R.C.P. has consulted for Roche, Inc., Merck, Inc., Biogen, Inc., Eisai, Inc. and Nestle, Inc., and served on a DSMB for Genentech, Inc. R.C.P. has received grants from the National Institute on Aging, the GHR Foundation and the Alzheimer’s Association.
Rights and permissions
About this article
Cite this article
Petersen, R.C. Are plasma markers for Alzheimer’s disease ready for clinical use?. Nat Aging 2, 94–96 (2022). https://doi.org/10.1038/s43587-022-00176-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43587-022-00176-1